Dawn Christine Maroney

ALHC President sells 30,000 shares at $19.55 via pre-arranged 10b5-1 plan; post-transaction holdings 947.3K shares.

President Maroney executed a scheduled sale of 30,000 shares (30.0K shares) for $586,425.00 ($586.4K) via a pre-arranged 10b5-1 trading plan, reducing her holdings by 3.1% to 947.3K shares. The transaction occurred while ALHC trades at -17.1% from its 52-week high of $23.87, and notably, Maroney's prior trade at this ticker on 2026-04-15 registered a -24.6% return over 30 days, signaling adverse timing outcomes in her recent ALHC-specific activity. Against broader context, ALHC's full-year net income was negative and the company sports a P/E of 197.80 with revenue of $1.2B, reflecting a high-valuation, early-stage profitability profile. Since this sale is governed by a pre-arranged plan, the transaction lacks discretionary intent signals; however, the convergence of a negative full-year result, elevated valuation multiples, and the -24.6% 30-day loss on her prior same-ticker sale warrants attention to ALHC's operational trajectory.

President Maroney Dawn Christine sold 30,000 shares of ALHC at $20.87; stock +19.5% in 30 days post-sale despite her 80% well-timed sell rate cross-ticker.

Maroney sold 30,000 shares (-2.8% of pre-transaction holdings) at $20.87 on 2026-04-15, reducing her stake to 1,028,813 shares. Notably, the stock has risen 19.5% in the 30 days following this sale, departing from her cross-ticker track record where she has achieved a 80.00% well-timed sell rate with an average 90-day return of -7.1% after her sells. At the same ticker, her prior four measurable sells have shown positive 30-day returns (+19.7%, +20.6%, +17.3%, -12.0%), suggesting a pattern of selling before rallies rather than declines. The company remains unprofitable on a full-year basis despite 46.1% annual revenue growth, and the stock trades at a 40.23 P/E multiple, creating an asymmetric risk environment where insider sells into strength warrant attention.

ALHC President Maroney sells 36,749 shares at $17.84; stock down 23.7% from 52-week high amid unprofitable year.

Maroney Dawn Christine, President of Alignment Healthcare, sold 36,749 shares (36.7K shares) at $17.84 on 2026-03-18 for $655.6K, reducing her stake from 1.10M to 1.06M shares. The sale occurs as ALHC trades 23.7% below its 52-week high and 11.8% lower over the prior 30 days, following a year in which the company remained unprofitable despite revenue growth of 46.1%. Her same-ticker history shows two prior sales just 2–6 days earlier (2026-03-16 and 2026-03-12), establishing a pattern of consecutive dispositions within a compressed timeframe. Cross-ticker, her prior 20 sales averaged -4.9% return over 90 days with a 70% well-timed rate; however, at ALHC specifically, none of her 5 prior measurable outcomes hit positive 90-day returns, suggesting ticker-specific divergence from her broader track record.

ALHC President Maroney sells 30,000 shares at $17.48 on 2026-03-16; stock down 11.2% in 30 days and 24.7% off 52-week high.

Maroney, the President of Alignment Healthcare, sold 30,000 shares (2.7% reduction from 1.13M to 1.10M shares) at $17.48 on 2026-03-16, with the stock currently trading 24.7% below its 52-week high of $23.81 and down 11.2% over the prior 30 days. Her cross-ticker track record shows a 63.64% well-timed rate on 20 prior sells across all tickers (average 90-day return -3.2%), suggesting a pattern of selling ahead of declines. However, at ALHC specifically, her 5 prior trades (all sells, conducted between 2026-01-15 and 2026-03-12) have not yet generated measurable 90-day outcomes, with the most recent prior sales on 2026-03-12 just placed. The company trades at a P/E of 34.46 on annualized revenue growth of 46.1%, though it remains unprofitable on a full-year basis ($3.7M net income against $993.7M revenue), and the stock's recent downward pressure may warrant attention to whether the insider's sales reflect broader concern or are part of routine liquidity management.

ALHC President Maroney sold 29,113 shares for $507,925.32 on 2026-03-12; stock -28.6% from 52-week high.

Maroney Dawn Christine, President of Alignment Healthcare, filed 2 separate sales totaling 29,113 shares for $507,925.32, reducing her holdings by 2.9%. The sales occurred at prices of $17.48 and $16.99 (blended average $17.45), against a current price of $16.99 and a 52-week high of $23.81—the stock has declined 28.6% from its peak and 16.7% over the last 30 days. At the company level, Alignment reported quarterly revenue of $993,695,000.00 and net income of $3,729,000.00, with strong annual revenue growth of 46.1%, yet the company was unprofitable over its full fiscal year. Maroney's prior five sales at ALHC show mixed near-term returns (ranging from +12.5% to -11.4% at the 30-day mark), and the 90-day outcome for her January and February trades at this ticker remains unmeasured. The concurrent weakness in the stock price and her discretionary sale during a significant drawdown warrant close attention to near-term developments and full 90-day measurement of this trade's timing relative to her historical patterns at this company.

ALHC: President Maroney sells 30,000 shares at $20.63; stock down 8.5% in 30 days and down 13.5% from 52-week high.

Maroney Dawn Christine, President of Alignment Healthcare, sold 30,000 shares (30.0K shares) at $20.63 on 2026-02-17, reducing holdings from 1,027,015 shares to 997,015 shares (a -2.9% reduction). The stock has declined 8.5% over the past 30 days and is currently 13.5% below its 52-week high of $23.81, trading at $20.59. At ALHC specifically, Maroney's prior 5 trades include two recent sales (on 2026-01-15) that have shown significant near-term declines of -11.4% and -9.0% respectively, though outcomes at the 90-day mark remain unmeasurable for all five same-ticker trades. The company's full-year net income was negative despite robust revenue growth of 48.2%, and current profitability remains marginal at $3.7M on $993.7M quarterly revenue. The timing of this sale within a recent downtrend and following a series of prior sales at this ticker merits monitoring, though the modest 2.9% reduction in holdings suggests a measured disposition rather than a aggressive exit.

ALHC President sold 30,000 shares (30.0K shares) for $674,450.94 on 2026-01-15; 5th sell in 2 weeks

Maroney Dawn Christine (President) executed 2 separate sales totaling 30,000 shares for $674,450.94 at blended average price $22.48, proximate to the current price of $22.50 and the 52-week high. This transaction reduces her ALHC holdings by 2.8% to 1,027,015 shares. The notable context is the frequency pattern: SAME-TICKER HISTORY shows 5 prior sells in the past month (four clustered 2026-01-06 through 2026-01-02, and three in 2025-12-29 through 2025-12-15), with the earliest measurable outcome (2025-12-15 sale) showing a +8.7% 30-day return for the stock—indicating the insider's prior sells at this ticker have not preceded declines. The company recently reported FY net income as negative, though latest-quarter net income was $3.7M and revenue grew +48.2% YoY, suggesting a turnaround inflection. With the stock near its 52-week high and rising sharply (+9.5% in 30 days, +31.4% in 90 days), frequent insider sales at peak valuation merit monitoring for sustainability of the rebound.

ALHC President Maroney sold 328,152 shares for $6.9M across two transactions, reducing holdings 23.7% to 1.06M shares

Maroney Dawn Christine, President of Alignment Healthcare, executed 2 separate sales totaling 328,152 shares for $6,871,050.10 at a blended average price of $20.94. The sales reduced her holdings from 1,385,167 shares to 1,057,015 shares—a 23.7% reduction. At the current price of $21.30, the stock is at its 52-week high with strong recent momentum (+9.0% over 30 days, +20.4% over 90 days). The company reported $993.7M in quarterly revenue with +48.2% annual growth, though it remains unprofitable on a full-year basis with net income of $3.7M in the latest quarter. This sale pattern—two transactions within four trading days after recent stock strength—occurs against a backdrop where the insider's prior trades at this same ticker have not been well-timed at the 90-day mark (0 of 1 measurable prior sells showed a subsequent decline), and her cross-ticker track record shows modest timing accuracy (41.67% well-timed rate with an average 90-day return of +3.2% after sells, indicating stocks typically rose after her previous sales across all tickers).

ALHC: Maroney (President) sells 282,070 shares for $5,286,747.38 on 2025-12-29; stock rising but insider selling into gains

Maroney Dawn Christine (President) executed two separate sales totaling 282,070 shares (282.1K shares) for $5,286,747.38 ($5.3M) at a blended average price of $18.74, reducing her post-transaction holdings to 1,385,167 shares (1.39M shares), a -16.9% reduction from prior holdings. The stock currently trades at $19.24, near its 52-week high of $20.55, with 90-day momentum of +14.4%, suggesting the insider sold into a period of sustained strength. This contrasts sharply with her same-ticker track record: in three prior measurable sales at ALHC on 2025-09-10, the stock subsequently rose by 2.7% to 6.7% over 30 days and 14.0% to 18.4% over 90 days, producing a 0% well-timed rate (all three sales preceded gains). The company remains unprofitable on a full-year basis despite strong revenue growth of +48.2%, adding to the complexity of valuation. Investors should note that Maroney has consistently sold into rallies at this ticker without prior benefit from downside protection, yet the current sale occurs near 52-week highs with no clear deterioration in market conditions.

ALHC President Maroney sells 130,000 shares (130.0K shares) for $2.6M as stock hits 52-week high of $20.11

Maroney Dawn Christine, President of Alignment Healthcare, executed two separate sales on 2025-12-12 and 2025-12-15, totaling 130,000 shares for $2,601,110.86 at a blended average price of $20.01, reducing her holdings by 7.2% to 1,667,237 shares. The sales occurred as ALHC's stock price reached its 52-week high of $20.11, up 21.7% over the preceding 30 days and 21.6% over 90 days. At this ticker, Maroney's prior five sales showed mixed execution: three sales in September 2025 were followed by strong 90-day gains of 17.0%, 14.0%, and 18.4% respectively, while a April 2025 sale preceded a 30.0% decline over 90 days, and a March 2025 sale was followed by a -9.4% 90-day return. The company reported quarterly revenue of $993,695,000.00 with annual revenue growth of 48.2%, though it remains unprofitable on a full-year basis with negative net income despite recent quarterly profitability of $3,729,000.00. The timing of this sale at a 52-week price high warrants observation against the backdrop of the company's strong top-line growth but ongoing profitability challenges.